2. Search Result
Search Result
Results for "

SARS-CoV-2 entry inhibitor

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Peptides

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156441
    SARS-CoV-2-IN-65

    		SARS-CoV Infection
    SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
    SARS-CoV-2-IN-65
  • HY-146157
    SARS-CoV-2-IN-22

    		SARS-CoV Infection
    SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM .
    SARS-CoV-2-IN-22
  • HY-161777
    SARS-CoV-2 Mpro-IN-23

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM .
    SARS-CoV-2 Mpro-IN-23
  • HY-P10803
    FLDKFNHEAEDLFYQSSL

    		SARS-CoV Infection
    FLDKFNHEAEDLFYQSSL is an 18-residue peptide that binds to SARS-CoV-2 receptor-binding domain (RBD). FLDKFNHEAEDLFYQSSL inhibits the entry of SARS-Cov-2. FLDKFNHEAEDLFYQSSL also interacts with binding residues (Leu455, Phe456, Ala475 and Gln493) .
    FLDKFNHEAEDLFYQSSL
  • HY-162550
    Jobosic acid

    		SARS-CoV Infection
    Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant .
    Jobosic acid
  • HY-149368
    SARS-CoV-2-IN-51

    		SARS-CoV Infection
    SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC50s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .
    SARS-CoV-2-IN-51
  • HY-170767
    SARS-CoV-2-IN-109

    		SARS-CoV Infection
    SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .
    SARS-CoV-2-IN-109
  • HY-169171
    Cathepsin L-IN-5

    		Cathepsin Infection
    Cathepsin L-IN-5 (D6-3) is a potent Cathepsin L (CatL) inhibitor with an IC50 of 0.27 nM. Cathepsin L-IN-5 effectively blocks the CatL function and substantially hinders the entry of the SARS-CoV-2 pseudovirus to cells by inhibiting the cleavage of the spike protein. Cathepsin L-IN-5 can be utilized in SARS-CoV-2 research .
    Cathepsin L-IN-5
  • HY-161844
    Virapinib

    		SARS-CoV Infection
    Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV .
    Virapinib
  • HY-121068
    Bisoxatin

    		Angiotensin-converting Enzyme (ACE) SARS-CoV Infection
    Bisoxatin is a laxative drug used for constipation. Bisoxatin binds substantially at the S-protein-ACE2 interface. Bisoxatin has the potential for inhibiting SARS-CoV-2 entry into the host research .
    Bisoxatin
  • HY-105086
    Pamaqueside

    CP148623

    		 SARS-CoV Infection Metabolic Disease
    Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research .
    Pamaqueside
  • HY-B1624
    Debrisoquin

    Debrisoquine; Isocaramidine; Ro 5-3307/1

    		 SARS-CoV Ser/Thr Protease Infection Cardiovascular Disease
    Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin can be used for antiviral research .
    Debrisoquin
  • HY-B1624A
    Debrisoquin hemisulfate

    Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate

    		 Endogenous Metabolite Infection Cardiovascular Disease
    Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin hemisulfate can be used for antiviral research .
    Debrisoquin hemisulfate
  • HY-148072
    MM3122

    		SARS-CoV Infection
    MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells .
    MM3122
  • HY-B1624C
    Debrisoquin hydrobromide

    Debrisoquine hydrobromide; Isocaramidine hydrobromide; Ro 5-3307/1 hydrobromide

    		 SARS-CoV Ser/Thr Protease Infection
    Debrisoquine (Ro 5-3307/1) hydrobromide is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquine hydrobromide can be used for antiviral research .
    Debrisoquin hydrobromide
  • HY-163029
    CTSL/B-IN-1

    		Cathepsin SARS-CoV Infection
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .
    CTSL/B-IN-1
  • HY-121068R
    Bisoxatin (Standard)

    		Angiotensin-converting Enzyme (ACE) SARS-CoV Infection
    Bisoxatin (Standard) is the analytical standard of Bisoxatin. This product is intended for research and analytical applications. Bisoxatin is a laxative drug used for constipation. Bisoxatin binds substantially at the S-protein-ACE2 interface. Bisoxatin has the potential for inhibiting SARS-CoV-2 entry into the host research .
    Bisoxatin (Standard)
  • HY-161068
    hACE2/SP-IN-1

    		SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    hACE2/SP-IN-1 (compound 7a) is a dual inhibitor of hACE2 and coronavirus spike protein. hACE2/SP-IN-1 can bind to the spike protein and block cell entry, preventing SARS-CoV-2 from infecting human cells .
    hACE2/SP-IN-1
  • HY-173459
    N-0920

    		SARS-CoV Infection
    N-0920 is a potent TMPRSS2 inhibitor with an IC50 of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC50s values of 300 pM and 90 pM, respectively .
    N-0920
  • HY-156655
    Olgotrelvir

    STI-1558

    		 SARS-CoV Virus Protease Cathepsin Infection
    Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
    Olgotrelvir
  • HY-156655A
    Olgotrelvir sodium

    STI-1558 sodium
    Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
    Olgotrelvir sodium
  • HY-16952
    Bepridil

    (±)-Bepridil; Org 5730

    		 Calcium Channel Sodium Channel SARS-CoV Infection Cardiovascular Disease
    Bepridil ((±)-Bepridil) is a calcium channel blocking agent used as antiarrhythmic agent. Bepridil inhibits both calcium and sodium currents, has research potential in certain ischemia-induced ventricular arrhythmias. Bepridil also has strong inhibition of SARS-CoV-2 from entry and replication inside Vero E6 and A549 cells .
    Bepridil
  • HY-107577
    Gedunin

    		HSP Infection Inflammation/Immunology Cancer
    Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .
    Gedunin
  • HY-108447
    BC-11 hydrobromide

    		Ser/Thr Protease SARS-CoV PAI-1 Infection Cancer
    BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer .
    BC-11 hydrobromide
  • HY-101984
    N6,N6-Dimethyladenosine
    2 Publications Verification

    		 Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV Infection Cancer
    N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines .
    N6,N6-Dimethyladenosine
  • HY-W195509
    Debrisoquin hydroiodide

    Debrisoquine hydroiodide; Isocaramidine hydroiodide; Ro 5-3307/1 hydroiodide

    		 SARS-CoV Ser/Thr Protease Infection
    Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research .
    Debrisoquin hydroiodide
  • HY-100211
    TAPI-2
    4 Publications Verification

    TNF Protease inhibitor 2

    		 MMP SARS-CoV Cancer
    TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP . TAPI-2 blocks the entry of infectious SARS-CoV .
    TAPI-2
  • HY-17437A
    Mefloquine hydrochloride
    3 Publications Verification

    Mefloquin hydrochloride

    		 Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase Infection Metabolic Disease Inflammation/Immunology Cancer
    Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K + channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .
    Mefloquine hydrochloride
  • HY-17437
    Mefloquine
    3 Publications Verification

    Mefloquin

    		 Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase Infection Metabolic Disease Inflammation/Immunology Cancer
    Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K + channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .
    Mefloquine
  • HY-101984R
    N6,N6-Dimethyladenosine (Standard)

    		Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV Infection Cancer
    N6,N6-Dimethyladenosine (Standard) is the analytical standard of N6,N6-Dimethyladenosine (HY-101984). This product is intended for research and analytical applications. N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines.
    N6,N6-Dimethyladenosine (Standard)
  • HY-100211A
    (R)-TAPI-2

    (R)-TNF Protease inhibitor 2

    		 SARS-CoV MMP Cancer
    (R)-TAPI-2 is the isomer of TAPI-2 (HY-100211A). TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP . TAPI-2 blocks the entry of infectious SARS-CoV .
    (R)-TAPI-2
  • HY-17437AR
    Mefloquine (hydrochloride) (Standard)

    		Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase Infection Metabolic Disease Inflammation/Immunology Cancer
    Mefloquine (hydrochloride) (Standard) is the analytical standard of Mefloquine (hydrochloride). This product is intended for research and analytical applications. Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .
    Mefloquine (hydrochloride) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: